Display options
Cite
Weiss M, Childress A, Nordbrock E, et al. Characteristics of ADHD Symptom Response/Remission in a Clinical Trial of Methylphenidate Extended Release. J Clin Med. 2019;8(4)doi: 10.3390/jcm8040461.
Weiss, M., Childress, A., Nordbrock, E., Adjei, A. L., Kupper, R. J., & Mattingly, G. (2019). Characteristics of ADHD Symptom Response/Remission in a Clinical Trial of Methylphenidate Extended Release. Journal of clinical medicine, 8(4), . https://doi.org/10.3390/jcm8040461
Weiss, Margaret, et al. "Characteristics of ADHD Symptom Response/Remission in a Clinical Trial of Methylphenidate Extended Release." Journal of clinical medicine vol. 8,4 (2019). doi: https://doi.org/10.3390/jcm8040461
Weiss M, Childress A, Nordbrock E, Adjei AL, Kupper RJ, Mattingly G. Characteristics of ADHD Symptom Response/Remission in a Clinical Trial of Methylphenidate Extended Release. J Clin Med. 2019 Apr 05;8(4). doi: 10.3390/jcm8040461. PMID: 30959790; PMCID: PMC6517933.
Copy Download .nbib Format: NLM
Share it on

J Clin Med. 2019 Apr 05;8(4). doi: 10.3390/jcm8040461.

Characteristics of ADHD Symptom Response/Remission in a Clinical Trial of Methylphenidate Extended Release.

Journal of clinical medicine

Margaret Weiss, Ann Childress, Earl Nordbrock, Akwete L Adjei, Robert J Kupper, Greg Mattingly

Affiliations

  1. Child and Adolescent Psychiatry, Cambridge Health Alliance, Cambridge, MA 02138, USA. [email protected].
  2. Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, NV 89128, USA. [email protected].
  3. Rhodes Pharmaceuticals L.P., Coventry, RI 02816, USA. [email protected].
  4. Rhodes Pharmaceuticals L.P., Coventry, RI 02816, USA. [email protected].
  5. Rhodes Pharmaceuticals L.P., Coventry, RI 02816, USA. [email protected].
  6. Washington University School of Medicine, Washington University, St. Louis, MO 63110, USA. [email protected].
  7. Midwest Research Group, St. Charles, MO 63304, USA. [email protected].

PMID: 30959790 PMCID: PMC6517933 DOI: 10.3390/jcm8040461

Abstract

Clinical trials in attention-deficit/hyperactivity disorder (ADHD) have typically measured outcome using clinician ratings on the Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV) and the Clinical Global Impression-Improvement (CGI-I) scale. Remission has been defined as an endpoint score of less than or equal to 18 on the ADHD-RS-IV (or a mean score of 1). Responders have been defined as patients who achieve a CGI-I score of much or very much improved (1 or 2). There is a lack of agreement in the literature on what percent change in symptoms on the ADHD-RS-IV should be used to define improvement or remission. This study uses data from a clinical trial of a methylphenidate extended release (MPH-MLR; Aptensio XR

Keywords: attention deficit/hyperactivity disorder; central nervous system stimulants; methylphenidate; remission; response

References

  1. Arch Gen Psychiatry. 1999 Dec;56(12):1073-86 - PubMed
  2. Am J Psychiatry. 2000 May;157(5):816-8 - PubMed
  3. J Am Acad Child Adolesc Psychiatry. 2001 Feb;40(2):168-79 - PubMed
  4. J Pediatr Psychol. 2003 Dec;28(8):559-67 - PubMed
  5. Can J Clin Pharmacol. 2006 Winter;13(1):e50-62 - PubMed
  6. Clin Ther. 2006 Nov;28(11):1892-908 - PubMed
  7. J Am Acad Child Adolesc Psychiatry. 2009 May;48(5):511-8 - PubMed
  8. Psychiatry (Edgmont). 2007 Jul;4(7):28-37 - PubMed
  9. J Atten Disord. 2011 Nov;15(8):674-83 - PubMed
  10. Child Adolesc Psychiatry Ment Health. 2011 May 11;5:14 - PubMed
  11. BMC Psychiatry. 2013 Jan 29;13:39 - PubMed
  12. CNS Drugs. 2013 Sep;27(9):743-51 - PubMed
  13. CNS Drugs. 2014 Nov;28(11):1059-69 - PubMed
  14. J Am Acad Child Adolesc Psychiatry. 2014 Oct;53(10):1092-101 - PubMed
  15. CNS Drugs. 2015 Apr;29(4):331-40 - PubMed

Publication Types